CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Evelo Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Evelo Biosciences Inc
124 WASHINGTON STREET, SUITE 101
Phone: (617) 577-0300p:617 577-0300 FOXBORO, MA  02035  United States Ticker: EVLOEVLO
This company ceased filing statements with the SEC on 1/26/2024.
On 11/20/2023, the Board of Evelo Biosciences Inc. determined that it is in the best interests of Evelo and its stockholders that the Company be dissolved in accordance with the General Corporation Law of the State of Delaware pursuant to a Plan of Dissolution.
Business Summary
Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. Its small intestinal axis (SINTAX) is the network of connections that links the small intestine and the rest of the body. Immune cells and other cells in the small intestine act as sentinels and are constantly sensing the contents of the gut. Depending on what is sensed, these cells relay messages from the gut to the rest of the body that modulate systemic immunity. Its orally delivered product candidates are pharmaceutical compositions of specific single strains of commensal microbes or the extracellular vesicles (EVs) they shed.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Principal Executive Officer, Principal Financial Officer and Principal Accounting Office Craig R.Jalbert 62 11/21/2023 11/21/2023
Chief Scientific Officer, President of Research and Development Mark W.Bodmer 68 4/1/2016 4/1/2016
General Counsel, Secretary Daniel S.Char 62 12/1/2018 12/1/2018
Chief Medical Officer DuncanMcHale 56 2/1/2018 2/1/2018
Chief Commercial Officer MarkPlinio 56 6/1/2021 6/1/2021

Business Names
Business Name
Evelo Biosciences (UK) Limited
Evelo Biosciences Security Corporation Massachusetts
EVLO

General Information
Number of Employees: 66 (As of 3/1/2023)
Outstanding Shares: 18,930,960 (As of 11/6/2023)
Shareholders: 26
Stock Exchange: OTC
Federal Tax Id: 465594527
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 28, 2025